Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma

ALV. Zumaya, S. Rimpelová, M. Štějdířová, P. Ulbrich, J. Vilčáková, F. Hassouna

. 2022 ; 23 (3) : . [pub] 20220121

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc22011279

Grant support
19-02889S Czech Science Foundation

Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The co-encapsulation of OXA and IO-OA was achieved in two types of polymeric carriers, namely, PLGA and poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) by double emulsion. PLGA_IO-OA_OXA and PEGylated PLGA_IO-OA_OXA nanoparticles displayed a comparable mean diameter of 207 ± 70 nm and 185 ± 119 nm, respectively. The concentration of the released OXA from the PEGylated PLGA_IO-OA_OXA increased very rapidly, reaching ~100% release after only 2 h, while the PLGA_IO-OA_OXA displayed a slower and sustained drug release. Therefore, for a controlled OXA release, non-PEGylated PLGA nanoparticles were more convenient. Interestingly, preservation of the superparamagnetic behavior of the IO-OA, without magnetic hysteresis all along the dissolution process, was observed. The non-PEGylated nanoparticles (PLGA_OXA, PLGA_IO-OA_OXA) were selected for the anti-CD133 Ab conjugation. The affinity of Ab-coated nanoparticles for CD133-positive cells was examined using fluorescence microscopy in CaCo-2 cells, which was followed by a viability assay.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011279
003      
CZ-PrNML
005      
20220506130935.0
007      
ta
008      
220425s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms23031200 $2 doi
035    __
$a (PubMed)35163122
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Zumaya, Alma Lucia Villela $u Faculty of Chemical Engineering, University of Chemistry and Technology Prague, 166 28 Prague, Czech Republic
245    10
$a Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma / $c ALV. Zumaya, S. Rimpelová, M. Štějdířová, P. Ulbrich, J. Vilčáková, F. Hassouna
520    9_
$a Anti-CD133 monoclonal antibody (Ab)-conjugated poly(lactide-co-glycolide) (PLGA) nanocarriers, for the targeted delivery of oxaliplatin (OXA) and superparamagnetic nanoparticles (IO-OA) to colorectal cancer cells (CaCo-2), were designed, synthesized, characterized, and evaluated in this study. The co-encapsulation of OXA and IO-OA was achieved in two types of polymeric carriers, namely, PLGA and poly(lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) by double emulsion. PLGA_IO-OA_OXA and PEGylated PLGA_IO-OA_OXA nanoparticles displayed a comparable mean diameter of 207 ± 70 nm and 185 ± 119 nm, respectively. The concentration of the released OXA from the PEGylated PLGA_IO-OA_OXA increased very rapidly, reaching ~100% release after only 2 h, while the PLGA_IO-OA_OXA displayed a slower and sustained drug release. Therefore, for a controlled OXA release, non-PEGylated PLGA nanoparticles were more convenient. Interestingly, preservation of the superparamagnetic behavior of the IO-OA, without magnetic hysteresis all along the dissolution process, was observed. The non-PEGylated nanoparticles (PLGA_OXA, PLGA_IO-OA_OXA) were selected for the anti-CD133 Ab conjugation. The affinity of Ab-coated nanoparticles for CD133-positive cells was examined using fluorescence microscopy in CaCo-2 cells, which was followed by a viability assay.
650    _2
$a antigen AC133 $x imunologie $7 D000071916
650    _2
$a monoklonální protilátky $x chemie $7 D000911
650    _2
$a protinádorové látky $x chemie $7 D000970
650    _2
$a kolorektální nádory $x farmakoterapie $x imunologie $x patologie $7 D015179
650    _2
$a nosiče léků $x chemie $7 D004337
650    12
$a lékové transportní systémy $7 D016503
650    _2
$a uvolňování léčiv $7 D065546
650    _2
$a lidé $7 D006801
650    _2
$a imunokonjugáty $x farmakologie $7 D018796
650    _2
$a nanočástice $x aplikace a dávkování $x chemie $7 D053758
650    _2
$a oxaliplatin $x chemie $7 D000077150
650    _2
$a kopolymer kyseliny glykolové a mléčné $x chemie $7 D000077182
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rimpelová, Silvie $u Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, 166 28 Prague, Czech Republic $1 https://orcid.org/0000000230081396 $7 xx0240185
700    1_
$a Štějdířová, Markéta $u Faculty of Chemical Engineering, University of Chemistry and Technology Prague, 166 28 Prague, Czech Republic
700    1_
$a Ulbrich, Pavel $u Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, 166 28 Prague, Czech Republic $1 https://orcid.org/0000000290768210 $7 xx0136336
700    1_
$a Vilčáková, Jarmila $u Faculty of Technology, Tomas Bata University, 760 01 Zlín, Czech Republic $1 https://orcid.org/0000000212162862
700    1_
$a Hassouna, Fatima $u Faculty of Chemical Engineering, University of Chemistry and Technology Prague, 166 28 Prague, Czech Republic $1 https://orcid.org/0000000179278416
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 23, č. 3 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35163122 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130927 $b ABA008
999    __
$a ok $b bmc $g 1789064 $s 1162477
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 23 $c 3 $e 20220121 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 19-02889S $p Czech Science Foundation
LZP    __
$a Pubmed-20220425

Find record

Citation metrics

Archiving options